Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Spago Nanomedical: Positive readout from second SPAGOPIX-01 cohort and expansion into additional indications

JU

CB

Johan Unnerus

Christian Binder

Redeye endorses Spago reporting clear contrast enhancement in the second SPAGOPIX-01 cohort, confirming positive interim results from the first cohort. Further, the company has plans to expand the study into documented pancreatic cancer with liver metastases. Today’s positive readout is in line with our expectations, and we reiterate our view that Spago has a bright future.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers